AstraZeneca reported robust H1 2024 performance with Total Revenue increasing 18% (CER) to $25.6B, driven by 18% growth in Product Sales and continued Alliance Revenue expansion. Core EPS grew 5% to $4.03, while Product Sales Gross Margin maintained at 82%.Growth was broad-based across therapeutic areas, with Oncology up 22%, CVRM up 22%, R&I up 22%, and Rare Disease up 15%. Key growth drivers included Farxiga (+38%), Ultomiris (+35%), and Enhertu (+62%). The company announced five positive Phase III studies that are expected to contribute meaningfully to future growth.Based on strong underlying performance, AstraZeneca upgraded its FY 2024 guidance, now expecting both Total Revenue and Core EPS to increase by mid-teens percentage at CER. The company declared an interim dividend of $1.00 per share, up 7 cents. Strategic investments included plans for a $1.5B ADC manufacturing facility in Singapore and acquisitions of Fusion Pharmaceuticals and Amolyt Pharma to strengthen the pipeline.

AstraZeneca reported robust H1 2024 performance with Total Revenue increasing 18% (CER) to $25.6B, driven by 18% growth in Product Sales and continued Alliance Revenue expansion. Core EPS grew 5% to $4.03, while Product Sales Gross Margin maintained at 82%.Growth was broad-based across therapeutic areas, with Oncology up 22%, CVRM up 22%, R&I up 22%, and Rare Disease up 15%. Key growth drivers included Farxiga (+38%), Ultomiris (+35%), and Enhertu (+62%). The company announced five positive Phase III studies that are expected to contribute meaningfully to future growth.Based on strong underlying performance, AstraZeneca upgraded its FY 2024 guidance, now expecting both Total Revenue and Core EPS to increase by mid-teens percentage at CER. The company declared an interim dividend of $1.00 per share, up 7 cents. Strategic investments included plans for a $1.5B ADC manufacturing facility in Singapore and acquisitions of Fusion Pharmaceuticals and Amolyt Pharma to strengthen the pipeline.